Sanofi-GSK announce vaccine trails success

Paris Sanofi and GlaxoSmithKline's potential Covid-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials after an earlier setback, boosting optimism the shot may join the fight against the pandemic this year.

After two doses of the vaccine candidate, participants showed neutralising antibodies in line with those found in people who had recovered from the disease, according to results of the Phase 2 trial released Monday.

The drug makers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021.